To: 5.1.2e [5.1.2e @rivm.nl]
From: 5.1.2e
Sent: Thur 1/21/2021 4:21:47 PM
Subject: FW: Zuid-afrikaanse variant ontwijkt mogelijk immuunsysteem
Received: Thur 1/21/2021 4:21:47 PM

5.1.2e 5.1.2e
[1]Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 |PO box 1 | 3720 BA BILTHOVEN | The Netherlands
[2]Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box 80165 | 3508 TD UTRECHT | The Netherlands
T: +31 (0)3 5.1.2e E: 5.1.2e @rivm.nl

From: 5.1.2e
Sent: donderdag 21 januari 2021 17:20
To: 5.1.2e < 5.1.2e @rivm.nl>
Subject: FW: Zuid-afrikaanse variant ontwijkt mogelijk immuunsysteem

"At first, the abstract to this paper seems very alarming, where the South African 501Y.V2 variant can escape neutralising antibody responses – due largely to the presence of the E484K and K417N mutations, which are also found in the Brazilian variant but not in the most widespread UK variant. This may reduce some efficacy from S-protein-based vaccine-induced antibodies in some people.

"However, later on, when discussing the convalescent plasma results (which are based on natural infection and exposure to the whole virus and all its proteins), the study notes considerable binding to the 501Y.V2 virus via other non-neutralising antibodies – which can still offer some significant protection against this virus variant.

"The study also acknowledges that it cannot assess the impact of this virus variant on T-cell responses (which act in a different way to antibodies) – so some additional defense will arise from this, as well as other naturally existing innate components of the immune system in those infected – in addition to any residual vaccine protection.

Het is niet rechtstreeks gemeten of vaccin-geinduceerde antistoffen wel of niet grip verliezen =

"Further real life studies will be needed to assess the true impact of this South African 501Y.V2 variant on the vaccinated South African population outside of a laboratory context – and in the presence of other natural human immune responses.

"In the mean time, we still need to continue with the COVID-19 vaccine programme and follow the current lockdown restrictions whilst we do this – to protect the vulnerable until they are vaccinated."

5.1.2e 5.1.2e [1,2]
[1]Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 |PO box 1 | 3720 BA BILTHOVEN | The Netherlands
[2]Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box 80165 | 3508 TD UTRECHT | The Netherlands
T: +31 (0)3 5.1.2e E: 5.1.2e @rivm.nl

5.1.2e 5.1.2e
5.1.2e 5.1.2e 5.1.2e 5.1.2e dubbel


dubbel